Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BerGenBio ASA ( (BRRGF) ) just unveiled an announcement.
BerGenBio ASA announced the closure of its BGBC016 study on bemcentinib for non-squamous Non-Small Cell Lung Cancer patients with STK11 mutations due to insufficient preliminary results to secure further funding. The company is exploring strategic alternatives, including potential sales or mergers, as it navigates financial challenges highlighted by a significant operating loss and negative cash flow for 2024.
More about BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL kinase as a potential cornerstone of therapy for aggressive diseases, including cancer. Based in Bergen, Norway, with a subsidiary in Oxford, UK, the company is listed on the Oslo Stock Exchange.
YTD Price Performance: 25.00%
Average Trading Volume: 37,305
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $35.85M
For an in-depth examination of BRRGF stock, go to TipRanks’ Stock Analysis page.